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Abstract
We assessed the relationship between atazanavir (ATV)-based antiretroviral treatment (ART) and plasma hepatitis
C virus (HCV) viral load in a population of HIV/HCV-coinfected patients. HIV/HCV-coinfected patients who
received ART based on a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) were
included. Patients were stratified by ART drug [ATV/rtv, lopinavir (LPV/rtv), efavirenz (EFV), nevirapine (NVP),
and other PIs], HCV genotype (1/4 and 2/3), and IL28B genotype (CC and non-CC). The Kruskal–Wallis test and
chi-squared test were used to compare continuous and categorical variables, respectively. Multivariate analysis
consisted of a stepwise linear regression analysis. Six hundred and forty-nine HIV/HCV-coinfected patients were
included. HCV genotype 1/4 patients who received ATV had higher HCV RNA levels [6.57 (5.9–6.8) log IU/ml]
than those who received LPV [6.1 (5.5–6.5) log IU/ml], EFV [6.1 (5.6–6.4) log IU/ml], NVP [5.8 (5.5–5.9) log IU/ml],
or other PIs [6.1 (5.7–6.4) log IU/ml] ( p= 0.014). This association held for the IL28B genotype (CC versus non-CC).
The association was not found in patients carrying HCV genotypes 2/3. The linear regression model identified the
IL28B genotype and ATV use as independent factors associated with HCV RNA levels. ATV-based therapy may be
associated with a higher HCV RNA viral load in HIV/HCV-coinfected patients.
Hemoglobin catabolism is closely related to the repli-cation of the hepatitis C virus (HCV).1 Heme oxygenase-
1 (HO-1) catalyzes the breakdown of the heme molecule to
yield equimolar quantities of biliverdin (BV), iron, and carbon
monoxide. The oxidation of heme by HO-1 releases at least
two antiviral agents, iron and BV.2 Lehman et al. reported that
BV has antiviral activity in replicon cells, noting that antiviral
activity was accompanied by a rise in specific interferon-
stimulated gene (ISG) products.2 Likewise, Zhu et al. recently
demonstrated that BV has potent antiviral activity against
HCV, with inhibitory action over HCV NS3/4A protease.3
Iron has also been shown to inhibit HCV replication by pre-
venting divalent caption binding to RdRp.4
Atazanavir (ATV) is a protease inhibitor used in HIV ther-
apy. ATV interfereswith hemoglobin catabolism because of its
competing inhibitory activity against the uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) enzyme, responsible
for bilirubin (BR) conjugation.5 This inhibition is directly
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associated with hyperbilirubinemia, the most common side
effect of patients treated with ATV boosted with ritonavir
(ATV/rtv). We hypothesize that this inhibition could modify
the modulatory effect of the products of hemoglobin catabo-
lism on HCV replication.
The aim of this study therefore was to assess the relation-
ship between the use of ATV-based antiretroviral treatment
(ART) and plasma HCV viral load in a population of HIV/
HCV-coinfected patients.
The study population was 829 HCV treatment-naive pa-
tientswho had been consecutively enrolled fromOctober 2004
to December 2011 in the Spanish HEPAVIR prospective co-
hort of HIV/HCV-coinfected patients. Further details of these
cohorts have been reported elsewhere.6 Patients who received
ART based on two ITIAN plus a protease inhibitor (PI) or
nonnucleoside reverse transcriptase inhibitors (NNRTI) were
included in the study. Patients who received estavudine, di-
danosine, or zidovudine were excluded from the study. Only
patients maintained for a minimum of time of 12 months on
an unchanged regimen were included. HCV RNA levels in
plasmawere measured using a commercial PCR assay (Cobas
Taqman; Roche Diagnostic Systems Inc., Pleasanton, CA:
detection limit of 50 IU/ml).
Liver fibrosis stage was determined by biopsy or liver
transient elastography (FibroScan, Echosen, Paris). Significant
fibrosis was defined as a METAVIR fibrosis score of F3–F4 in
liver biopsy or a liver stiffness (LS) value of ‡ 8.9. SNP
rs129679860, located 3 kilobases upstream of the IL28B gene,
was genotyped using a custom Taqman assay (Applied Bio-
systems, Foster City, CA) on DNA isolated from whole blood
samples. The bilirubin data of those patients on ATV/rtv
treatment were also collected. Patients were stratified by ART
drug [ATV/rtv, lopinavir (LPV), efavirenz (EFV), nevirapine
(NVP), or other PI (saquinavir, nelfinavir, darunavir, or in-
dinavir)], HCV genotype (1/4 and 2/3), and IL28B genotype
(CC and non-CC). The Kruskal–Wallis test and chi-squared
test were used to compare continuous and categorical vari-
ables, respectively. Post hoc comparisons between groups
were carried out using the Mann–Whitney U test and the chi-
squared test. To test our hypothesis, we used the Pearson or
the bivariate Spearman’s rank correlation coefficient to ana-
lyze the relationship between HCV viral load and bilirubin
levels among patients treated with ATV/rtv. Associations
with p values of < 0.05 were considered significant for com-
parisons between groups. Multivariate analysis consisted of a
stepwise linear regression analysis.
Six hundred and forty-nine HIV/HCV-coinfected patients
were included in the analysis. Forty patients (7.3%) were
treated with ATV/rtv, 128 (23.4%) with LPV/rtv, 225 (41.2%)
with EFV, 41 (7.5%) with NVP, and 112 (20.5%) received some
other PI. Only nine patients who might have been included in
the analysis and fulfilled the criteria for inclusion in the study
were receiving darunavir/r. Given the low number of pa-
tients, we decided not to include them as an independent
group for analysis The most significant characteristics are
shown in Table 1.
Median HCV RNA levels of HCV genotypes 1/4 and 2/3
were 6.13 (5.6–6.7) log IU/ml and 5.7 (5.3–6.2) log IU/ml,
respectively ( p< 0.001). HCV genotype 1/4 patients who re-
ceived ATV/rtv had higher HCV RNA levels [6.57 (6.2–6.8)
log IU/ml] than those receiving LPV/rtv [6.1 (5.5–6.5) log
IU/ml], EFV [6.1 (5.6–6.4) log IU/ml], NVP [5.8 (5.5–5.9) log
IU/ml], or another PI drug [6.1 (5.7–6.4) log IU/ml
( p= 0.014)]. However, this association was not found in
patients bearing HCV genotype 2/3 [ATV/rtv: 5.74 (5.4–5.9)
log IU/ml], LPV/rtv [5.7 (5.2–5.8) log IU/ml], EFV [5.8 (5.6–6)
log IU/ml], NVP [5.3 (4.9–5.5) log IU/ml], and other PI drug
[5.6 (5.4–5.9) log IU/ml, p= 0.34].
The IL28B-CC genotype was associated with a higher HCV
viral load than the non-CC genotype [6.3 (6.2–6.6) log IU/ml
versus 6 (5.9–6.3) log IU/ml, p = 0.001]. There were no dif-
ferences in HCV viral load found on the basis of detectable
HIV viral load [detectable, 6.1 (5.8–6.4) versus undetectable
6 (5.4–6.2), p= 0.247] or liver fibrosis stage [advanced liver
fibrosis: 6.2 (5.8–6.5) versus absence of liver fibrosis stage: 6.1
(5.9–6.3), p= 0.472]. When HCV RNA viral loads were
analyzed in terms of the drug used for ART, patients with
IL28B-CC receiving ATV/rtv had higher viral loads than
those receiving another drug [ATV/rtv: 7.3 (6.9–7.4) log
IU/ml; LPV/rtv: 6.6 (6.2–6.8) log IU/ml; EFV: 6.6 (6.3–6.8) log
IU/ml; other PI: 6.4 (6.2–6.9) log IU/ml, p= 0.038]. Patients
with IL28B non-CC receiving ATV had higher baseline HCV
viral loads than those receiving another ART regimen [ATV/
rtv: 6.15 (6–6.4) log IU/ml; LPV/rtv: 5.9 (5.8–6.2) log IU/ml;
EFV: 5.8 (5.6–6) log IU/ml; other PIs: 5.9 (5.8–6.1) log IU/ml,
p = 0.032]. The mean ( – SD) bilirubin level among those
patients who received ATV/rtv was 2.31 – 0.87. In these
patients, HCV viral load correlated positively with bilirubin
levels (r= 0.39; p = 0.0129).
Table 2 shows the linear regression model. Independent
factors associatedwithHCVRNA levels were IL28B genotype
Table 1. Baseline Population Characteristics
Characteristics
N 649
Age (years), mean (SD) 40.8 (5.56)
Male gender, n (%) 537 (82.7)
AIDS criteria, n (%) 192 (29.6)
HbsAg positive, n (%) 8 (1.2)
Undetectable HIV viral load, n (%) 472 (72.7)
CD4 cell count (cells/mm3), mean (SD) 518 (266)
HCV genotype 1/4, n (%) 452 (69.6)
Liver cirrhosis stage, n (%) 154 (23.7)
IL28B-CC genotype, n (%)a 115 (38.1)
aAvailable for 302 patients.
SD, standard deviation; AIDS, acquired immunodeficiency syn-
drome criteria in the past; HbsAg, hepatitis B surface antigen; IL28B,
interleukin 28B.
Table 2. Linear Regression Model for Hepatitis C
Virus Baseline Viral Load in Patients Bearing
the Hepatitis C Virus Genotype 1
Variable Condition B p
IL28B CC 0.7 0.033
ATV/rtv Use 0.8 0.017
Liver fibrosis stage Significant 0.075 0.884
HIV viral load Undetectable 0.18 0.321
R2 = 0.22.
B, adjusted coefficient; IL28B, interleukin 28B; ATV/rtv, atazana-
vir boosted with ritonavir; HIV, human immunodeficiency virus.
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(B = 2.7; p = 0.033) and use of ATV (B = 2.8; p = 0.017). R2 was
0.22.
This is the first study to show the association between
ATV/rtv use and HCV RNA viral load. Since a high HCV
RNA viral load is a risk factor for nonresponse to treatment,
this may be an important issue in conditioning the response to
pegylated-interferon (PEG-IFN) with ribavirin (PEG-IFN/
RBV) or to therapy based on NS3 protease inhibitors in HIV/
HCV genotype 1-coinfected patients.7–9 However, the rela-
tionship between ATV/rtv and treatment response has not
yet been analyzed.
The reason ATV use might be associated with higher HCV
RNA viral loads is unknown. In vitro studies have reported
that BR and BV show antiviral activity against HIV, the herpes
virus, and HCV.3 More specifically, the antiviral action
against HCV is due to both recombinant and endogenous
NS3/4A protease from replicon microsomes being inhibited
by BR and BV.3 HO-1, on the other hand, potentiates inter-
feron (IFN)-a, and so enhances antiviral activity.2 Hyperbi-
lirubinemia and ATV use are directly associated because of
ATV’s competing inhibitory activity against UGT1A1, re-
sponsible for BR conjugation in the liver. Inhibition may
modify hemoglobin catabolism by suppressing various en-
zymes with antiviral activity against HCV (BR-R, BV-S, and
HO-1) due to the enhancement of the resulting metabolite
(BR) or reduced ISG activity (from the inhibition or down-
regulation of HO-1). There is no evidence that ATV blocks the
activity of HO-1, in addition to inhibiting UGT1A1. However,
a clinical trial is currently in progress whose secondary ob-
jective is to determine the effect of atazanavir-induced hy-
perbilirubinemia on HO-1 induction (NCT00916448), which
may clarify this question. On the other hand, our study
showed that NVP use was associated with lower HCV viral
load, as has previously been reported by our group.10
Our study has several limitations. First, the number of
patients with ATV-based therapy was relatively low. Second,
the design was not a randomized study, which may have led
to bias not being recognized. Third, no concomitant drugs
were considered in the analysis. Fourth, although BR is closely
related to ATV/rtv use, BR levels were not collected. Fifth, no
concomitant diseases were analyzed in our study, and it is
known that several liver pathologies may condition BR levels,
as Gilbert’s syndrome.
In conclusion, on the basis of our results, ATV-based ther-
apy may be associated with higher HCV RNA viral loads
among HIV/HCV-coinfected patients, a finding that could
have an important impact on the outcome of HCV therapy.
Studies are needed to confirm the relationship found in our
study, as well to analyze this association in HCV treatment
response.
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